Chimerix (NASDAQ:CMRX) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Chimerix (NASDAQ:CMRX) from a hold rating to a sell rating in a research note released on Tuesday.

A number of other research firms have also weighed in on CMRX. HC Wainwright restated a buy rating and set a $11.00 price objective on shares of Chimerix in a research note on Friday, March 1st. Wedbush reiterated an outperform rating and issued a $6.00 price target on shares of Chimerix in a research note on Monday, February 12th.

Chimerix Stock Performance

NASDAQ:CMRX opened at $0.94 on Tuesday. The firm has a market cap of $84.45 million, a P/E ratio of -1.01 and a beta of 1.13. Chimerix has a fifty-two week low of $0.88 and a fifty-two week high of $1.57. The firm has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $1.00.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. During the same quarter in the prior year, the business earned ($0.24) EPS. On average, equities research analysts predict that Chimerix will post -0.85 EPS for the current year.

Institutional Trading of Chimerix

Several large investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. bought a new stake in Chimerix during the third quarter valued at approximately $6,240,000. Acadian Asset Management LLC grew its position in Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 291,981 shares during the period. Vestal Point Capital LP bought a new stake in Chimerix during the fourth quarter valued at approximately $1,348,000. Bank of New York Mellon Corp grew its position in Chimerix by 190.0% during the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock valued at $568,000 after buying an additional 387,638 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Chimerix by 17.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock valued at $481,000 after buying an additional 72,719 shares during the period. 45.42% of the stock is currently owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.